Efficacy and Safety of Ertugliflozin in Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Front Pharmacol · 2021 · PMC8811446 · PMID 35126103

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

For different dosages considered, only the use of 5 mg ertugliflozin was found to significantly decrease DBP levels (WMD −0.877 mmHg; 95% CI −1.695 to −0.059; I 2 = 61.6%), although the use of 15 mg ertugliflozin was associated with a decreasing trend (WMD −0.586 mmHg; 95% CI −1.209 to 0.037; I 2 = 38.3%), with a P interaction of 0.579.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.